Abstract: The present invention relates to a compound represented by Formula 1 wherein A, B, L, X, and R1 to R6 are as described herein, or a pharmaceutically acceptable salt thereof, which serves as a GLP-1 receptor agonist and may be useful in the prevention or treatment of a disease associated with GLP-1 activity.

Abstract: Provided is an optical communication system including: a remote control device for generating OAM (Operation, Administration, and Maintenance) signal including OAM information for equipment, converting the OAM signals to OAM optical signals, overlaying the OAM optical signals and communication upstream signals transmitted to a Communication Stations device, and controlling the transmission of the overlaid signals to the Communication Stations device; and the Communication Stations device for generating OAM control signals, converting the OAM control signal to OAM optical control signals, overlaying the OAM optical control signals and optical communication downstream signals transmitted to the remote control device, and controlling the transmission of the overlaid control signals to the remote control device.

Abstract: The present invention relates to an anticancer composition comprising an antitumor agent as well as a substance having inhibitory effects on the activity or expression of L1CAM; more particularly, to an anticancer composition, which comprises an anti-L1CAM antibody specific to L1CAM, serving as a substance for inhibiting the activity of L1CAM; an oligonucleotide inhibiting the generation of L1CAM, serving as a substance for inhibiting the expression of L1CAM; and a substance selected from cisplatin, gemcitabine, 5-fluorouracil and taxol, serving as an antitumor agent.